How docs view the ALS data

Since June, when data from pivotal trials of Cephalon Inc.'s Myotrophin IGF-1 and Rhone-Poulenc Rorer's Rilutek (riluzole) first enabled comparisons between the two drugs, Wall Street gradually has come to the conclusion that Myotrophin will be the commercial winner in the amyotrophic lateral sclerosis market.

That conclusion was enhanced by the presentation of data at RPR's FDA advisory panel meeting, at which the panel narrowly endorsed approval of the drug (see BioCentury Extra, Sept. 19). At the meeting, the FDA, the advisory committee, RPR and ALS advocates all agreed that the benefits of the drug are marginal, with a three-month survival benefit and no discernible improvement in the quality of life...